2024
Joint bleeds in mild hemophilia: Prevalence and clinical characteristics
Chiari J, Prozora S, Feinn R, Louizos E, Gallagher P, Bona R. Joint bleeds in mild hemophilia: Prevalence and clinical characteristics. Haemophilia 2024, 30: 331-335. PMID: 38240020, DOI: 10.1111/hae.14939.Peer-Reviewed Original ResearchMild haemophiliaJoint bleedsJoint range of motionHepatitis CRange of motionMild diseaseHistory of joint bleedsInstitutional review board approvalJoint rangeRetrospective chart reviewHemophilia treatment centersReview board approvalJoint healthHistory of traumaDisease burdenMedical recordsChart reviewClinical characteristicsMitigate disease burdenRisk factorsBoard approvalBleedingTraumatic bleedingAverage ageHemophilic arthropathy
2023
Comprehensive Characterization of Coagulation Parameters in Venous Malformations
Restrepo V, Pine A, Butt A, Chang E, Bar N, Baluha A, Brooks A, Chirico G, Curran J, Dumont A, Obura-Wilkes P, Rinder H, Tormey C, Nassiri N, Lee A, Prozora S. Comprehensive Characterization of Coagulation Parameters in Venous Malformations. Blood 2023, 142: 27. DOI: 10.1182/blood-2023-190609.Peer-Reviewed Original ResearchHigher thrombin-antithrombin complexesNormal D-dimerThrombin-antithrombin complexPlasminogen activator inhibitor-1Localized intravascular coagulopathyInternational normalized ratioD-dimerVenous malformationsCoagulation parametersPartial thromboplastin timeCoagulation testsFactor VIIIVWF activityChart reviewMost patientsHematology clinicProthrombin timeTissue involvementVWF antigenVon Willebrand factor antigenHigher TAT levelsMultiple coagulation parametersBaseline patient characteristicsRetrospective chart reviewCoagulation test resultsMultimodality Platelet Evaluation By Mass Cytometry and Genetic Analysis in Patients with Bleeding Disorders
Gu S, Gallagher P, Butt A, Gu V, Lezon-Geyda K, Schulz V, Prozora S, Lee A, Neparidze N, Bar N, Martin K, Cornell J, Chirico G, Chakraborty R, Rinder H, Hwa J, Bona R. Multimodality Platelet Evaluation By Mass Cytometry and Genetic Analysis in Patients with Bleeding Disorders. Blood 2023, 142: 1197. DOI: 10.1182/blood-2023-177946.Peer-Reviewed Original ResearchBleeding tendencyBleeding disorderPlatelet markersPlatelet aggregometryMass cytometryPlatelet functionPlatelet disordersSingle-center prospective studyLow-risk groupAbnormal bleeding tendencyQualitative platelet disordersLarge patient cohortQuantitative platelet disordersCommon underlying causeGenetic variantsMultimodality evaluationTotal patientsRisk stratificationLaboratory suspicionPlatelet dysfunctionProspective studyPatient cohortUnivariate analysisPlatelet volumeRisk groups
2022
Current practices in pediatric hospital‐acquired thromboembolism: Survey of the Children's Hospital Acquired Thrombosis (CHAT) Consortium
Abrams C, Jaffray J, Stillings A, Branchford B, Young G, Goldenberg N, Abajas Y, Investigators F, SSC T, Fargo J, Crary S, Kumar R, Woods G, Narang S, Cooper J, Silvey M, Garland K, Mahajerin A, Luchtman‐Jones L, Torres M, Wright J, Pahl K, Armstrong K, Braunreiter C, Bakeer N, Sochet A, Hogan M, Gupta S, Knoll C, Hege K, Schaefer B, Panigrahi A, Thornburg C, Shimano K, Ahuja S, Weyand A, Boucher A, Abajas Y, Subbaswamy A, Khan O, Druzgal C, Maida D, Wheeler A, Malec L, Branchford B, Kucine N, Prozora S. Current practices in pediatric hospital‐acquired thromboembolism: Survey of the Children's Hospital Acquired Thrombosis (CHAT) Consortium. Research And Practice In Thrombosis And Haemostasis 2022, 6: e12793. PMID: 38024326, PMCID: PMC10656282, DOI: 10.1002/rth2.12793.Peer-Reviewed Original ResearchHospital-acquired venous thromboembolismCentral venous cathetersVTE prophylaxisRisk factorsVTE risk assessment modelAcute systemic inflammationGlobal coronavirus disease 2019Coronavirus disease 2019Majority of providersPharmacologic prophylaxisProphylactic anticoagulationSurvey response rateSystemic inflammationVenous cathetersVenous thromboembolismHospital guidelinesGuideline implementationPediatric hospitalDosing strategiesDisease 2019ProphylaxisResponse rateDrug monitoringRisk assessmentAge groupsIntentional overdose of rivaroxaban and alcohol: A case report
Hamidi R, Sowa A, Halperin‐Goldstein S, Puthenpura V, Prozora S. Intentional overdose of rivaroxaban and alcohol: A case report. Pediatric Blood & Cancer 2022, 70: e29969. PMID: 36094312, DOI: 10.1002/pbc.29969.Peer-Reviewed Original ResearchPractice patterns and real-life outcomes for patients with acute promyelocytic leukemia in the United States
Bewersdorf JP, Prozora S, Podoltsev NA, Shallis R, Huntington SF, Neparidze N, Wang R, Zeidan AM, Davidoff AJ. Practice patterns and real-life outcomes for patients with acute promyelocytic leukemia in the United States. Blood Advances 2022, 6: 376-385. PMID: 34724703, PMCID: PMC8791583, DOI: 10.1182/bloodadvances.2021005642.Peer-Reviewed Original ResearchConceptsAcute promyelocytic leukemiaAdverse outcomesPromyelocytic leukemiaNational Comprehensive Cancer Network guidelinesBaseline white blood cell countFavorable long-term prognosisWhite blood cell countVizient Clinical Data BaseGuideline-concordant regimensGuideline-concordant therapyGuideline-concordant treatmentGuideline-recommended therapiesBaseline clinical characteristicsHigh-risk diseaseLong-term prognosisPopulation-based registryBlood cell countClinical data baseLarge database analysisLogistic regression modelsTreatment concordanceClinical characteristicsReal-world practiceTreatment patternsNetwork guidelines
2021
Clinical decision rule for obtaining peripheral blood cultures in febrile oncology patients
Gorfinkel L, Hansen CE, Teng W, Shabanova V, Prozora S, Rodwin R, Qadri U, Manghi T, Emerson B, Riera A. Clinical decision rule for obtaining peripheral blood cultures in febrile oncology patients. Pediatric Blood & Cancer 2021, 69: e29519. PMID: 34939321, DOI: 10.1002/pbc.29519.Peer-Reviewed Original ResearchConceptsPediatric emergency departmentPeripheral blood culturesPediatric oncology patientsFebrile oncology patientsClinical decision ruleOncology patientsBlood culturesBloodstream infectionsPositive peripheral blood cultureDiagnostic prediction toolsInternal validationRetrospective chart reviewAcute myeloid leukemia diagnosisRecent systematic reviewClinical prediction modelReceiver operator curveVasopressor supportActive therapyChart reviewDerivation cohortIndependent predictorsEmergency departmentPatientsSystematic reviewOperator curve
2020
Patterns of medication use at end of life by pediatric inpatients with cancer
Prozora S, Shabanova V, Ananth P, Pashankar F, Kupfer GM, Massaro SA, Davidoff AJ. Patterns of medication use at end of life by pediatric inpatients with cancer. Pediatric Blood & Cancer 2020, 68: e28837. PMID: 33306281, DOI: 10.1002/pbc.28837.Peer-Reviewed Original ResearchConceptsMedication usePediatric inpatientsVizient Clinical Database/Resource ManagerHematopoietic stem cell transplantLife-sustaining medicationsMedication utilization patternsSymptom management medicationsUse of opioidsStem cell transplantIntensive care unitLength of stayAcademic medical centerResource use dataLast weekWarrants further studyEvidence-based approachVasopressor useEnd of lifeCare unitCell transplantMedication categoriesResuscitate statusRetrospective studyMalignancy typeOdds ratioAssessing Advanced Communication Skills via Objective Structured Clinical Examination: A Comparison of Faculty Versus Self, Peer, and Standardized Patient Assessors
Talwalkar JS, Murtha TD, Prozora S, Fortin AH, Morrison LJ, Ellman MS. Assessing Advanced Communication Skills via Objective Structured Clinical Examination: A Comparison of Faculty Versus Self, Peer, and Standardized Patient Assessors. Teaching And Learning In Medicine 2020, 32: 294-307. PMID: 32141335, DOI: 10.1080/10401334.2019.1704763.Peer-Reviewed Original Research
2019
Etoposide phosphate for pediatric orthopedic malignancies after intravenous etoposide hypersensitivity
Brooks JP, Azmy V, Thompson A, Luon D, Prozora SD, Price C, Hsu FI. Etoposide phosphate for pediatric orthopedic malignancies after intravenous etoposide hypersensitivity. Journal Of Oncology Pharmacy Practice 2019, 26: 228-231. PMID: 30885040, DOI: 10.1177/1078155219836478.Peer-Reviewed Original ResearchConceptsOrthopedic malignanciesHypersensitivity reactionsEtoposide phosphatePediatric patientsEtoposide hypersensitivityLarge academic medical centerAcademic medical centerCase of etoposideContinued therapyChart reviewFurther therapyFirst dosesFull dosesEwing's sarcomaMedical CenterPatientsMalignancySafe alternativeEtoposideHypersensitivityTherapyDiphenhydramineDosesPremedicationSarcoma
2018
An Initiative to Decrease Time to Antibiotics for Patients With Fever and Neutropenia
Emerson BL, Prozora S, Jacob A, Clark K, Kotrady D, Edwards L, Ciaburri R, Riera A. An Initiative to Decrease Time to Antibiotics for Patients With Fever and Neutropenia. American Journal Of Medical Quality 2018, 34: 158-164. PMID: 30078347, DOI: 10.1177/1062860618792305.Peer-Reviewed Original ResearchConceptsMultidisciplinary teamRapid Plan-DoPediatric emergency departmentStudy-Act cyclesEfficiency of careAntibiotic administrationEmergency departmentVulnerable patientsPlan-DoPatientsNeutropeniaAverage timeFeverInterventionProcess control chartsData reviewDecrease timeAntibioticsSignificant improvementAdministration